Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: Meta-analysis of placebo-controlled trials

Advances in Therapy

Volumn 29, Issue 9, 2012, Pages 736-746

  Monami, Matteo ^a   Vitale, Valentina ^b   Ambrosio, Maria Luisa ^a   Bartoli, Nadia ^a   Toffanello, Giulia ^a   Ragghianti, Benedetta ^b   Monami, Francesca ^a   Marchionni, Niccolò ^a   Mannucci, Edoardo ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acarbose; Dipeptidyl peptidase 4 inhibitor; Lipid profile; Pioglitazone; Sulfonylureas; Type 2 diabetes

Indexed keywords

ACARBOSE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LINAGLIPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; VILDAGLIPTIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ACARBOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 84866516615     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0045-5     Document Type: Review

References (56)

1. Avogaro A, Giorda C, Maggini M, et al. Incidence of coronary heart disease in type 2 diabetic men and women: Impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007;30:1241-7. (Pubitemid 46684654)
2. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91. (Pubitemid 351214285)
3. American Diabetes Association. Standards of Medical Care in Diabetes 2012. Available at: care. diabetesjournals.org/content/35/Supplement-1/S11.full. pdf+html. Accessed Jan 1 2012.
4. International Diabetes Federation. Guide for Guidelines. Available at: www.idf.org/webdata/docs/Guide-for-Guidelines.pdf. Accessed Jan 1 2012.
5. Societa Italiana de Diabetologia. Guidelines [in Italian]. Available at: www.siditalia.it/pubblicazioni/linee-guida.html. Accessed Jan 1 2012.
6. Tan CE, Chew LS, Chio LF et al. Cardiovascular risk factors and LDL subfraction profile in type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res Clin Pract. 2001;51:107-14. (Pubitemid 32140862)
7. Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: A stable isotope kinetic study. Eur J Clin Invest. 2000;30:685-94. (Pubitemid 30604069)
8. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-8.
9. Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab. 1999;25(Suppl. 3):32-40. (Pubitemid 29299745)
10. Derosa G, Salvadeo SA. Pioglitazone and rosiglitazone: Effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr Clin Pharmacol. 2008;3:77-84.
11. Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J Intern Med. 2004;256:1-14. (Pubitemid 38813614)
12. Rosenstock J, Kim SW, Baron MA et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-85. (Pubitemid 46206561)
13. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:959-69.
14. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: Systematic review and meta-analysis. Adv Ther. 2012;29:14-25.
15. Aschner P, Katzeff HL, Guo H, Sunga S, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:252-61.
16. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6:133-56. (Pubitemid 38220106)
17. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA. 2003;290:486-94. (Pubitemid 37430502)
18. Eleftheriadou I, Grigoropoulou P, Katsilambros N, Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr Diabetes Rev. 2008;4:340-56.
19. Mori Y, Itoh Y, Obata T, Tajima N. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine. 2006;29:143-8. (Pubitemid 43780357)
20. Araki T, Emoto M, Konishi T et al. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism. 2009;58:143-8.
21. Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis. Diabetes Res Clin Pract. 2008;79:196-203.
22. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303:1410-8.
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151:264-9.
24. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
25. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34. (Pubitemid 27387172)
26. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995;98:443-51.
27. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-9.
28. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care. 1998;21:1462-9. (Pubitemid 28405197)
29. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005;366:1279-89. (Pubitemid 41416583)
30. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. Diabetes Care. 2000;23:1605-11.
31. Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel- group study. Clin Ther. 2005;27:554-67. (Pubitemid 40835966)
32. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:442-51.
33. Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-85. (Pubitemid 46206561)
34. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39:218-23. (Pubitemid 46580622)
35. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: A randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315-7.
36. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11:167-76.
37. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65-74.
38. Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2010;94:4810-9.
39. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24- week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556-68. (Pubitemid 44841980)
40. Yoon KH, Shockey GR, Teng R, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011;65:154-64.
41. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638-43. (Pubitemid 44912191)
42. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab. 2009;11:611-22.
43. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin. 2007;23:945-52. (Pubitemid 46631497)
44. Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223:133-5.
45. Breuer HW. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther. 2003;41:421-40.
46. Papanas N, Maltezos E. Oral antidiabetic agents: Anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des. 2009;15:3179-92.
47. Derosa G, Cicero AF, Fogari E, D'Angelo A, Bianchi L, Maffioli P. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Horm Metab Res. 2011;43:505-12.
48. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2008;10:1221-38.
49. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53.
50. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65.
51. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors. A meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27(Suppl. 3):57-64.
52. AstraZeneca. SAVOR-TIMI 53 (Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications). Identifier: NCT01107886. Available at: clinicaltrials.gov/ct2/show/NCT01107886? term =type+2+diabetes+mellitus+and+cardiovascular+di sease&rank=37. Accessed Dec 27 2011.
53. Merck. TECOS (Sitagliptin Cardiovascular Outcome Study). Identifier: NCT 00790205. Available at: clinicaltrials.gov/ct2/show/NCT00790205. Accessed Dec 27 2011.
54. Takeda Global Research & Development Center, Inc. Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE). Identifier: NCT00968708. Available at: clinicaltrials.gov/ ct2/show/NCT00968708. Accessed Dec 27 2011.
55. Boehringer Ingelheim Pharmaceuticals. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes. Identifier: NCT01243424. Available at: clinicaltrials.gov/ct2/show/NCT01243424. Accessed Dec 27 2011.
56. Nicholls SJ, Tuzcu EM, Wolski K, et al. Lowering the triglyceride/high- density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: Insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J Am Coll Cardiol. 2011;57:153-9.